Search Results - "Evan, Carolyn"

Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer by Hamid, Anis A., Gray, Kathryn P., Shaw, Grace, MacConaill, Laura E., Evan, Carolyn, Bernard, Brandon, Loda, Massimo, Corcoran, Niall M., Van Allen, Eliezer M., Choudhury, Atish D., Sweeney, Christopher J.

“…TP53, PTEN, and RB1 tumor suppressor genes (TSGs) are recurrently altered in treatment-resistant prostate cancer. Cooperative loss of two or more TSGs may…”
Get full text

Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry by Francini, Edoardo, Gray, Kathryn P., Shaw, Grace K., Evan, Carolyn P., Hamid, Anis A., Perry, Caitlin E., Kantoff, Philip W., Taplin, Mary-Ellen, Sweeney, Christopher J.

“…Background In 2004, docetaxel was shown to prolong the overall survival (OS) of patients with metastatic castration-resistance prostate cancer (mCRPC). Since…”
Get full text

Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer by Francini, Edoardo, Yip, Steven, Ahmed, Shubidito, Li, Haocheng, Ardolino, Luke, Evan, Carolyn P., Kaymakcalan, Marina, Shaw, Grace K., Kantoff, Philip W., Taplin, Mary-Ellen, Alimohamed, Nimira S., Joshua, Anthony M., Heng, Daniel Y.C., Sweeney, Christopher J.

“…Although an androgen deprivation therapy plus docetaxel regimen was shown to extend the survival of some patients with metastatic hormone-sensitive prostate…”
Get full text

Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center by Muralidhar, Vinayak, Regan, Meredith M, Werner, Lillian, Nakabayashi, Mari, Evan, Carolyn P, Bellmunt, Joaquim, Choueiri, Toni K, Elfiky, Aymen A, Harshman, Lauren C, McKay, Rana R, Pomerantz, Mark M, Sweeney, Christopher J, Taplin, Mary-Ellen, Kantoff, Philip W, Nguyen, Paul L

“…Micro-Abstract We evaluated the patterns of androgen deprivation therapy (ADT) use for high-risk prostate cancer at a tertiary referral cancer center…”
Get full text

Impact of new systemic therapies on outcomes of patients with non-metastatic castration resistant prostate cancer (nmCRPC) by Vicier, Cecile, Xie, Wanling, Hamid, Anis, Evan, Carolyn, Sweeney, Christopher

“…Abstract only 244 Background: Treatments and outcomes of men with nmCRPC in routine care are poorly described. We assessed the cumulative impact of new…”
Get full text

Association between CD8 and PD‐L1 expression and outcomes after radical prostatectomy for localized prostate cancer by Vicier, Cecile, Ravi, Praful, Kwak, Lucia, Werner, Lillian, Huang, Ying, Evan, Carolyn, Loda, Massimo, Hamid, Anis A., Sweeney, Christopher J.

“…Background Characterization of markers of both immune suppression and activation may provide more prognostic information than assessment of single markers in…”
Get full text

Immune infiltrate with CD8 low or PDL1 high associated with metastatic prostate cancer after radical prostatectomy (RP) by Vicier, Cecile, Werner, Lillian, Huang, Ying, Hamid, Anis, Evan, Carolyn, Loda, Massimo, Sweeney, Christopher

“…Abstract only 86 Background: Given limited information about the prostate cancer (PC) immune infiltrate in men with localized disease, we profiled 6 markers…”
Get full text

Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease by Tsao, Che-kai, Gray, Kathryn P, Nakabayashi, Mari, Evan, Carolyn, Kantoff, Philip W, Huang, Jiaoti, Galsky, Matthew D, Pomerantz, Mark, Oh, William K

“…Purpose We examined differences in outcome in patients with biopsy Gleason score 8 vs 9-10 who received definitive local therapy. Materials and Methods Using…”
Get full text

Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases by McGregor, Bradley, Zhang, Li, Gray, Kathryn P., Shaw, Grace, Evan, Carolyn, Francini, Edoardo, Sweeney, Christopher

“…Background In an era of multiple life-prolonging therapies for metastatic castration resistant prostate cancer (mCRPC), the optimal timing of initiation and…”
Get full text

Bone targeted therapy and skeletal related events in the era of modern therapies for castration resistant prostate cancer with bone metastases by Zhang, Li, Gray, Kathryn P., Shaw, Grace, Evan, Carolyn, Francini, Edoardo, Sweeney, Christopher

“…Abstract only…”
Get full text

Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival by Sharma, Jaya, Gray, Kathryn P., Harshman, Lauren C., Evan, Carolyn, Nakabayashi, Mari, Fichorova, Raina, Rider, Jennifer, Mucci, Lorelei, Kantoff, Philip W., Sweeney, Christopher J.

“…BACKGROUND Chemokines and cytokines have been implicated in progression to castration‐resistant prostate cancer (CRPC). METHODS Retrospective data were…”
Get full text

DNA damage and repair (DDR) gene variants and outcomes in localized and metastatic prostate cancer (mPC) by Bernard, Brandon David, Gray, Kathryn P., Shaw, Grace, MacConaill, Laura E, Evan, Carolyn, Hamid, Anis, Choudhury, Atish Dipankar, Sweeney, Christopher

“…Abstract only 304 Background: Moderate frequencies of DDR gene variants exist in mPC. Their prognostic role in localized and mPC is unclear. This study aims to…”
Get full text

Tumor suppressor aberrations and outcomes in localized and metastatic hormone sensitive prostate cancer (PrCa) by Hamid, Anis, Gray, Kathryn P., Shaw, Grace, MacConaill, Laura E, Evan, Carolyn, Bernard, Brandon David, Choudhury, Atish Dipankar, Sweeney, Christopher

“…Abstract only 184 Background: Aberrations of tumor suppressors (TS) TP53, PTEN and RB1 are recurrent genomic events in PrCa and associated with adverse…”
Get full text

Clinical outcomes with cumulative tumor suppressor gene (TSG) alterations in castration sensitive (CSPC) and resistant (CRPC) prostate cancer by Hamid, Anis, Gray, Kathryn P., Shaw, Grace, MacConaill, Laura E, Evan, Carolyn, Bernard, Brandon David, Loda, Massimo, Choudhury, Atish Dipankar, Sweeney, Christopher

“…Abstract only…”
Get full text

Impact of new systemic therapies on overall survival (OS) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) in a hospital-based registry by Francini, Edoardo, Gray, Kathryn P., Shaw, Grace, Evan, Carolyn, Hamid, Anis, Perry, Caitlin E, Kantoff, Philip W., Taplin, Mary-Ellen, Sweeney, Christopher

“…Abstract only 203 Background: From 2004 to 2009, mCRPC treatment options were limited to docetaxel (D), mitoxantrone, first generation anti-androgens (AA),…”
Get full text

Outcomes of prechemotherapy (pCHT) abiraterone (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) + docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based registry by Francini, Edoardo, Gray, Kathryn P., Evan, Carolyn, Kaymakcalan, Marina D., Shaw, Grace Katherine, Kantoff, Philip W., Taplin, Mary-Ellen, Sweeney, Christopher

“…Abstract only e16515 Background: The E3805: CHAARTED trial noted use of D at time of commencing ADT for mHSPC was associated with an improvement in time to…”
Get full text

Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival by Sharma, Jaya, Gray, Kathryn P., Evan, Carolyn, Nakabayashi, Mari, Fichorova, Raina, Rider, Jennifer, Mucci, Lorelei, Kantoff, Philip W., Sweeney, Christopher J.

“…BACKGROUND Insulin‐like growth factor (IGF) and adipokines have been implicated in prostate cancer carcinogenesis. METHOD Data from 122 men with serum samples…”
Get full text

Duration of androgen deprivation therapy for high-risk prostate cancer: Application of randomized trial data in a tertiary referral cancer center by Muralidhar, Vinayak, Regan, Meredith M., Werner, Lillian, Nakabayashi, Mari, Evan, Carolyn, Bellmunt, Joaquim, Choueiri, Toni K., Elfiky, Aymen, Harshman, Lauren Christine, McKay, Rana R., Pomerantz, Mark, Sweeney, Christopher, Taplin, Mary-Ellen, Kantoff, Philip W., Nguyen, Paul L.

“…Abstract only 33 Background: We wished to evaluate the incidence and predictors of the use of long-term (2-3 years) vs. shorter-term androgen deprivation…”
Get full text

Characterization of patients who present with de novo metastatic prostate cancer: Single-institution database analysis by Strock, Jessica, Gray, Kathryn P., Nakabayashi, Mari, Evan, Carolyn, O'Donnell, Elizabeth, Pomerantz, Mark, Kantoff, Philip W., Sweeney, Christopher

“…Abstract only 33 Background: Less than 5% of men in a PSA screened population present with denovo metastatic prostate cancer. We sought to characterize the…”
Get full text

Elevated IL-8, TNF-[alpha], and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival by Sharma, Jaya, Gray, Kathryn P, Harshman, Lauren C, Evan, Carolyn, Nakabayashi, Mari, Fichorova, Raina, Rider, Jennifer, Mucci, Lorelei, Kantoff, Philip W, Sweeney, Christopher J

“…BACKGROUND Chemokines and cytokines have been implicated in progression to castration-resistant prostate cancer (CRPC). METHODS Retrospective data were…”
Get full text